AR073365A1 - Preparacion farmaceutica solida de liberacion sostenida - Google Patents
Preparacion farmaceutica solida de liberacion sostenidaInfo
- Publication number
- AR073365A1 AR073365A1 ARP090103419A ARP090103419A AR073365A1 AR 073365 A1 AR073365 A1 AR 073365A1 AR P090103419 A ARP090103419 A AR P090103419A AR P090103419 A ARP090103419 A AR P090103419A AR 073365 A1 AR073365 A1 AR 073365A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical preparation
- solid pharmaceutical
- sugar
- preparation according
- alcohol
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 7
- 239000007787 solid Substances 0.000 title abstract 7
- 230000002459 sustained effect Effects 0.000 title 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 2
- 239000007884 disintegrant Substances 0.000 abstract 2
- 239000010419 fine particle Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000845 maltitol Substances 0.000 abstract 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 abstract 2
- 235000010449 maltitol Nutrition 0.000 abstract 2
- 229940035436 maltitol Drugs 0.000 abstract 2
- 235000012239 silicon dioxide Nutrition 0.000 abstract 2
- HBDJFVFTHLOSDW-DNDLZOGFSA-N (2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;hydrate Chemical compound O.O=C[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HBDJFVFTHLOSDW-DNDLZOGFSA-N 0.000 abstract 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract 1
- ZCWBZRBJSPWUPG-UHFFFAOYSA-N 4-bromo-2-nitroaniline Chemical compound NC1=CC=C(Br)C=C1[N+]([O-])=O ZCWBZRBJSPWUPG-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 239000004386 Erythritol Substances 0.000 abstract 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 abstract 1
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920000148 Polycarbophil calcium Polymers 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 abstract 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical group CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
- 229940095498 calcium polycarbophil Drugs 0.000 abstract 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 abstract 1
- 229950008138 carmellose Drugs 0.000 abstract 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract 1
- 150000004683 dihydrates Chemical class 0.000 abstract 1
- 235000019414 erythritol Nutrition 0.000 abstract 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 abstract 1
- 229940009714 erythritol Drugs 0.000 abstract 1
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 abstract 1
- 239000000832 lactitol Substances 0.000 abstract 1
- 235000010448 lactitol Nutrition 0.000 abstract 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 abstract 1
- 229960003451 lactitol Drugs 0.000 abstract 1
- 229960001159 lactitol monohydrate Drugs 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 229960001375 lactose Drugs 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 229960002160 maltose Drugs 0.000 abstract 1
- 229960003017 maltose monohydrate Drugs 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229960001855 mannitol Drugs 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 abstract 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 229960002920 sorbitol Drugs 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 abstract 1
- 229940074410 trehalose Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000811 xylitol Substances 0.000 abstract 1
- 235000010447 xylitol Nutrition 0.000 abstract 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 abstract 1
- 229960002675 xylitol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Una preparacion farmacéutica solida tipo matriz que comprende: (a) una sustancia farmacologicamente activa; (b) calcio policarbofilo; y (c) un azucar y)o un azucar alcohol, siendo (c) azucar y/o azucar alcohol por lo menos un miembro seleccionado del grupo consistente de trehalosa, lactitol, maltosa, maltitol, sacarosa, sorbitol, xilitol, erithritol, manitol, lactosa, e isomaltooligosacárido. Reivindicacion 4: La preparacion farmacéutica solida de acuerdo con la reivindicacion 1, que comprende adicionalmente (d) partículas finas insolubles en agua. Reivindicacion 7: La preparacion farmacéutica solida de acuerdo con la reivindicacion 4, que comprende adicionalmente (e) un desintegrante tipo mecha. Reivindicacion 8: La preparacion farmacéutica solida de acuerdo con la reivindicacion 7, donde el (e) desintegrante tipo mecha es carmelosa. Reivindicacion 9: La preparacion farmacéutica solida de acuerdo con la reivindicacion 4, donde las (d) partículas finas insolubles en agua son por lo menos un miembro seleccionado de grupo consistente de dioxido de silicio coloidal, dioxido de silicio hidratado, ácido silícico anhídrido ligero, talco, oxido de titanio, estearato de magnesio y etil celulosa. Reivindicacion 14: La preparacion farmacéutica solida de acuerdo con la reivindicacion 1, donde el (c) azucar y/o azucar de alcohol es por lo menos un miembro seleccionado del grupo consistente de monohidrato de maltosa, maltitol, monohidrato de lactitol, y dihidrato de trehalosa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008228569 | 2008-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073365A1 true AR073365A1 (es) | 2010-11-03 |
Family
ID=41226333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103419A AR073365A1 (es) | 2008-09-05 | 2009-09-04 | Preparacion farmaceutica solida de liberacion sostenida |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9173844B2 (es) |
| EP (1) | EP2328560A1 (es) |
| JP (2) | JP5745399B2 (es) |
| KR (1) | KR20110052731A (es) |
| CN (1) | CN102143738A (es) |
| AR (1) | AR073365A1 (es) |
| CA (1) | CA2736024A1 (es) |
| TW (1) | TW201010743A (es) |
| WO (1) | WO2010026971A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919864A (zh) * | 2010-06-21 | 2010-12-22 | 天津市汉康医药生物技术有限公司 | 托伐普坦药物组合物及其制备方法 |
| CN102552278A (zh) * | 2010-12-23 | 2012-07-11 | 天津泰普药品科技发展有限公司 | 一种提高难溶性药物托伐普坦溶出度的药物组合物 |
| CN104487094B (zh) | 2012-07-20 | 2017-05-17 | 大塚制药株式会社 | 表面具有干燥油墨被膜的片剂、及用于喷墨打印机的油墨 |
| TWI615157B (zh) * | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | 包括不定形西洛他唑的固體分散劑 |
| TWI660748B (zh) * | 2013-03-01 | 2019-06-01 | 日商大塚製藥股份有限公司 | 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液 |
| JP7161176B2 (ja) * | 2017-07-11 | 2022-10-26 | トーアエイヨー株式会社 | 口腔内崩壊錠及びその製造方法 |
| CN111888335A (zh) * | 2020-08-21 | 2020-11-06 | 福安药业集团重庆礼邦药物开发有限公司 | 一种托伐普坦的药物固体制剂及制备方法 |
| WO2023128905A1 (en) * | 2021-12-30 | 2023-07-06 | Santa Farma Ilac Sanayii A.S. | Pharmaceutical composition comprising amorphous tolvaptan |
| WO2023158411A1 (en) * | 2022-02-18 | 2023-08-24 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A tablet of tolvaptan and at least one binder processed with wet granulation |
| CN117100703B (zh) * | 2023-09-21 | 2025-12-05 | 河北龙海药业有限公司 | 一种托伐普坦固体分散体及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0273209B1 (en) * | 1986-12-30 | 1992-01-15 | American Cyanamid Company | Composition of matter containing polycarbophil |
| ATE137404T1 (de) * | 1990-08-21 | 1996-05-15 | Theratech Inc | Zusammensetzungen zur kontrollierten freigabe |
| DE4036757A1 (de) * | 1990-11-17 | 1992-05-21 | Bayer Ag | Antazida-zubereitung mit verlaengerter magenverweilzeit |
| JP2609022B2 (ja) | 1990-11-29 | 1997-05-14 | 北陸製薬株式会社 | ポリカルボフィルカルシウム含有製剤 |
| JPH07126163A (ja) * | 1993-10-08 | 1995-05-16 | Theratech Inc | 制御放出性ピロカルピン送達システム |
| GB9514842D0 (en) | 1995-07-20 | 1995-09-20 | Smithkline Beecham Plc | Novel formulation |
| WO2003013609A1 (fr) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Medicaments a liberation continue |
| US6984653B2 (en) * | 2001-10-05 | 2006-01-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof |
| US20040151771A1 (en) * | 2003-02-04 | 2004-08-05 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
| MXPA06000417A (es) * | 2003-07-10 | 2006-03-17 | Smithkline Beecham Corp | Composiciones farmaceuticas. |
| JP4567640B2 (ja) * | 2005-07-29 | 2010-10-20 | 田辺三菱製薬株式会社 | 小型化塩酸サルポグレラート経口投与製剤 |
-
2009
- 2009-08-25 TW TW098128507A patent/TW201010743A/zh unknown
- 2009-08-26 WO PCT/JP2009/065283 patent/WO2010026971A1/en not_active Ceased
- 2009-08-26 KR KR1020117007728A patent/KR20110052731A/ko not_active Withdrawn
- 2009-08-26 US US13/062,389 patent/US9173844B2/en not_active Expired - Fee Related
- 2009-08-26 EP EP09788054A patent/EP2328560A1/en not_active Withdrawn
- 2009-08-26 JP JP2011510209A patent/JP5745399B2/ja not_active Expired - Fee Related
- 2009-08-26 CN CN200980134688XA patent/CN102143738A/zh active Pending
- 2009-08-26 CA CA2736024A patent/CA2736024A1/en not_active Abandoned
- 2009-09-04 AR ARP090103419A patent/AR073365A1/es unknown
-
2015
- 2015-01-06 JP JP2015001041A patent/JP2015061887A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110165249A1 (en) | 2011-07-07 |
| CN102143738A (zh) | 2011-08-03 |
| JP2015061887A (ja) | 2015-04-02 |
| CA2736024A1 (en) | 2010-03-11 |
| JP5745399B2 (ja) | 2015-07-08 |
| TW201010743A (en) | 2010-03-16 |
| WO2010026971A1 (en) | 2010-03-11 |
| KR20110052731A (ko) | 2011-05-18 |
| US9173844B2 (en) | 2015-11-03 |
| EP2328560A1 (en) | 2011-06-08 |
| JP2012501960A (ja) | 2012-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073365A1 (es) | Preparacion farmaceutica solida de liberacion sostenida | |
| ES2565464T3 (es) | Pastilla medicamentosa con liberación lenta del principio activo | |
| ES2262999T3 (es) | Composicion farmaceutica orodispersable de agomelatina. | |
| NZ598993A (en) | Multi-portion intra-oral dosage form with organoleptic properties | |
| ES2320753T3 (es) | Pastillas que se disgregan oralmente y procedimiento para obtenerlas. | |
| AR069128A1 (es) | Forma de dosificacion que se desintegra oralmente y proceso de preparacion | |
| ES2987493T3 (es) | Comprimido oral desintegrable de edoxaban tosilato hidrato | |
| KR20130076015A (ko) | 높은 경도를 갖는 속붕정 및 이의 제조 방법 | |
| JP6073543B2 (ja) | ロラタジン含有口腔内崩壊錠の製造方法 | |
| ES2633088T3 (es) | Comprimido estable que contiene droxidopa | |
| ES2282062T1 (es) | Composicion farmaceutica que contiene irbesartan. | |
| CO6150122A2 (es) | Comprimidos pediatricos de capecitabina | |
| WO2011048563A2 (en) | Orally disintegrating tablets of betahistine | |
| KR20190087569A (ko) | 카바메이트 화합물을 포함하는 구강 붕해 정제 | |
| EA201170695A1 (ru) | Улучшенная стабильность таблеток карбоната кальция при растворении | |
| EP2826465B1 (en) | Orally disintegrating tablet formulations of donepezil | |
| JP2007197357A5 (es) | ||
| ES3049195T3 (en) | Pharmaceutical capsule composition of rivaroxaban | |
| AR070530A1 (es) | Comprimido de desintegracion oral | |
| KR20130076511A (ko) | 환경에 민감한 약물에 적합한 속붕정 및 이의 제조 방법 | |
| EP2959889A1 (en) | Orally disintegrating formulations of loxoprofen | |
| US20090062404A1 (en) | Pharmaceutical composition | |
| JP6012373B2 (ja) | 口腔内崩壊錠 | |
| ES2314440T3 (es) | Composicion farmaceutica bucodispersable de un compuesto antitrombotico. | |
| JP2011173848A (ja) | 口腔内速崩壊錠 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |